PARP1 and pulmonary arterial hypertension: A further animal study showed that the PARP inhibitor veliparib (ABT-888) reduces RV pressure and reverses PAH development as well as RV hypertrophy in sugen-hypoxia- and monocrotaline-induced rat models.